Skip to search formSkip to main contentSkip to account menu

UCN 01

Known as: (+)-UCN-01, UCN-01 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

7-hydroxystaurosporine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.
Interactions between UCN-01 and HMG-CoA reductase inhibitors (ie, statins) have been examined in human leukemia and myeloma cells… 
Highly Cited
2006
Highly Cited
2006
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
BACKGROUND 7-Hydroxystaurosporine (UCN-01) inhibits serine-threonine kinases including the Ca2+ and phospholipid-dependent… 
Highly Cited
2005
Highly Cited
2005
A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.
Purpose: To define the maximum tolerated dose and the dose-limiting toxicity of the kinase modulator UCN-01 administered as a… 
Highly Cited
2002
Highly Cited
2002
Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.
The effects of combined exposure to the checkpoint abrogator UCN-01 and pharmacologic MEK1/2 inhibitors were examined in human… 
Highly Cited
2002
Highly Cited
2002
Structural basis for Chk1 inhibition by UCN-01.
Chk1 is a serine-threonine kinase that plays an important role in the DNA damage response, including G(2)/M cell cycle control… 
Highly Cited
2001
Highly Cited
2001
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
PURPOSE To define the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of the novel protein kinase inhibitor, UCN-01… 
Highly Cited
2000
Highly Cited
2000
UCN‐01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G2 checkpoint abrogation
We have previously reported that UCN‐01 (7‐hydroxystaurosporine), a protein kinase inhibitor that is under clinical trials as an… 
Highly Cited
2000
Highly Cited
2000
UCN-01 Enhances the In Vitro Toxicity of Clinical Agents in Human Tumor Cell Lines
UCN-01 is undergoing Phase I evaluation and is a candidate forcombination strategies in the clinic. UCN-01 has been shown to… 
Highly Cited
1999
Highly Cited
1999
Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans.
The large species difference in the pharmacokinetics/pharmacodynamics of 7-hydroxystaurosporine (UCN-01) can be partially… 
Highly Cited
1999
Highly Cited
1999
Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins.
UCN-01, an anticancer agent currently in Phase I clinical trials, has been found to potentiate the cytotoxicity of cisplatin… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)